Search research articles
Contact Us
Filters
Showing results (351-360 of 471) with videos related to
Page
of 48
Sort By:
European Journal of Heart Failure
|
October 2, 2015
Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease
Natalie A Bello, Eldrin F Lewis, Akshay S Desai, et al.
European Heart Journal
|
January 8, 2013
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial
Andrew P Ambrosy, Peter S Pang, Sadiya Khan, et al.
European Journal of Heart Failure
|
February 10, 2021
Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis
Luis E Rohde, Muthiah Vaduganathan, Brian L Claggett, et al.
European Heart Journal
|
February 4, 2017
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF
Michael Böhm, Robin Young, Pardeep S Jhund, et al.
JACC. Heart Failure
|
March 14, 2014
The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial
Stephen J Greene, Muthiah Vaduganathan, Jane E Wilcox, et al.
Journal of the American College of Cardiology
|
May 27, 2017
Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators
Kenneth C Bilchick, Yongfei Wang, Alan Cheng, et al.
The American Journal of Cardiology
|
October 15, 2014
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial)
Muthiah Vaduganathan, Stephen J Greene, Andrew P Ambrosy, et al.
European Journal of Cardiovascular Nursing
|
July 19, 2011
Person-centered care--ready for prime time
Inger Ekman, Karl Swedberg, Charles Taft, et al.
European Journal of Heart Failure
|
April 27, 2010
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme
Su Min Chang, Christopher B Granger, Peter A Johansson, et al.
European Journal of Heart Failure
|
April 2, 2010
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme
Nathaniel M Hawkins, Duolao Wang, Mark C Petrie, et al.
Page
of 48
Search research articles
Search
Showing results (351-360 of 471) with videos related to
Sort By:
Page
of 48
European Journal of Heart Failure
|
October 2, 2015
Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease
Natalie A Bello, Eldrin F Lewis, Akshay S Desai, et al.
European Heart Journal
|
January 8, 2013
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial
Andrew P Ambrosy, Peter S Pang, Sadiya Khan, et al.
European Journal of Heart Failure
|
February 10, 2021
Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis
Luis E Rohde, Muthiah Vaduganathan, Brian L Claggett, et al.
European Heart Journal
|
February 4, 2017
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF
Michael Böhm, Robin Young, Pardeep S Jhund, et al.
JACC. Heart Failure
|
March 14, 2014
The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial
Stephen J Greene, Muthiah Vaduganathan, Jane E Wilcox, et al.
Journal of the American College of Cardiology
|
May 27, 2017
Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators
Kenneth C Bilchick, Yongfei Wang, Alan Cheng, et al.
The American Journal of Cardiology
|
October 15, 2014
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial)
Muthiah Vaduganathan, Stephen J Greene, Andrew P Ambrosy, et al.
European Journal of Cardiovascular Nursing
|
July 19, 2011
Person-centered care--ready for prime time
Inger Ekman, Karl Swedberg, Charles Taft, et al.
European Journal of Heart Failure
|
April 27, 2010
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme
Su Min Chang, Christopher B Granger, Peter A Johansson, et al.
European Journal of Heart Failure
|
April 2, 2010
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme
Nathaniel M Hawkins, Duolao Wang, Mark C Petrie, et al.
Page
of 48